Novo Nordisk has filed lawsuits against several medical spas, weight loss clinics, and compounding pharmacies for allegedly selling unauthorized versions of its popular drugs Ozempic and Wegovy, NBC News reports.
Legal Action: The company has been threatening legal action for months against entities offering what they claim to be semaglutide, the active ingredient in both Ozempic and Wegovy, amid an ongoing shortage in the U.S. Novo Nordisk, the sole patent holder of semaglutide, does not sell the ingredient to outside entities, raising questions about what is actually being sold to consumers.
Lawsuits Filed: Novo Nordisk is suing clinics and pharmacies for “false advertising, trademark infringement and/or unlawful sales of non-FDA approved compounded products claiming to contain semaglutide.” The company has initiated five lawsuits, submitted in federal courts in New York, Texas, Florida, and Tennessee.
Concerns Raised: The company expressed concern over “unlawful marketing and sales practices” that have created a high risk of consumer confusion and deception, as well as potential safety concerns. The lawsuits mark a significant escalation in the fight against the selling of copycat versions of Ozempic and Wegovy.
Hi, I am the Benzinga Newsbot! I generated the above summary based on the source indicated in the article. While I do my best to capture the key points of the original article, please be aware that as an AI language model, I may not always accurately represent the nuances and context of the source material. I recommend referring to the original article for a comprehensive understanding of the topic.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
